• Keine Ergebnisse gefunden

Institut de Biologie et de

N/A
N/A
Protected

Academic year: 2022

Aktie "Institut de Biologie et de "

Copied!
23
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

1

Institut de Biologie et de

Technologie de Saclay

(2)

2

(3)

3

(4)

Radiobiology: Understand the effect of low doses of radiation on living matter.

Nuclear and nanoparticles toxicology : Determine the impact of the new technologies on man and environment.

Bioenergies : Study the alive and be inspired by it to design new sources of energy

Biotechnologies: Make the industry of the biotechnologies benefit of the innovations of the research.

Imaging and medical research : Improve the knowledge, diagnose more prematurely, elaborate and validate innovative therapeutic strategies.

Genomics: Know the structure of the genome and determine the individual predispositions to certain pathologies

4

Research topics at DSV

(5)

5

CEA : 4 Operational Divisions

Sciences of Matter Nuclear

Fundamental Research Technological

Research Defence

SciencesLife

(6)

6

• 450 people (250 CEA workers, 50 PhDs, 50 Postdocs)

Joint Research Units with

– CNRS (National Center for Scientific Research ),

– INRA (French National Institute of Agricultural Research) – University Paris VII and Paris XI

Industrial research teams with

– BioMérieux

– Bertin Pharma (SPI-Bio) – Proteus

– Profilomic

Ibitech-S key figures

(7)

7

Expertise

(8)

8

Basic and applied research areas

(9)

9

iBiTec-S Platforms

Infrastructures for research on prion diseases

High-safety infrastructure – Level 3 laboratories and animal houses.

Screening facilities for bioactive molecules

A combinatorial chemistry and high- throughput screening facility

Spectroscopy platform Study of the physico-chemical properties of membrane proteins involved in the primary phase of light

energy conversion

Si RNA platform

Genome wide siRNA library covering 22950 human genes

Monoclonal antibodies platform Automate for production, screening

of antibodies

(10)

Hervé VOLLAND

Head of Laboratory for Studies and Research in Immunoanalysis

Laboratory for Studies and Research in Immunoanalysis

(LERI)

(11)

11

CEA : 4 Operational Divisions

Sciences of Matter Nuclear

Fundamental Research Technological

Research Defence

SciencesLife

(12)

A glimpse of history A glimpse of history

Since its origin (1980) the LERI has pursued two goals:

Since its origin (1980) the LERI has pursued two goals:

-Research valorisation-Research valorisation

-Development of immunological techniques-Development of immunological techniques

Competences acquired:

Competences acquired:

- Production of polyclonal and monoclonal antibodies- Production of polyclonal and monoclonal antibodies - Labelling- Labelling of moleculesof molecules

- Development of original immunoassay formats- Development of original immunoassay formats - - Actual validation of immunoassaysActual validation of immunoassays

(13)

Prion Diseases

Bioterrorism

Environment

Antibody for medical purpose

Lateral Flow Immunoassays

Immunoliposomes Immunoassays

Continuous Detection Protein Biochemistry

Molecular Biology Microbiology

LERI: Technologies and Application domains LERI: Technologies and Application domains

Laboratory

of Studies and Researches in Immunoanalysis

Immunoanalysis Antibody Production

Autoimmune Disease:

Diabetes

(14)

LERI: Collaborations and interactions LERI: Collaborations and interactions

iBiTeC-S

IBEB

Groupement de Recherche:

Groupement de Recherche:

Anticorps et Th Anticorps et Théérapierapie

Laboratoire d’Etudes et de

Recherche en Immunoanalyse

18 Persons 6 Researchers

5 Technicians 3 PhD students

4 Temporary

(15)

Antibody production

Since the beginning the LERI produced and characterized Abs to develop immunoassays.

> 1700 Monoclonal antibodies

> 120 Targets (drugs, peptides, proteins) This led to:

(16)

16

- Botulinum neurotoxin A: 14 monoclonal antibodies - Botulinum neurotoxin B: 15 monoclonal antibodies - Botulinum neurotoxin E: 17 monoclonal antibodies - Botulinum neurotoxin F: 28 monoclonal antibodies - Botulinum neurotoxin G: 9 monoclonal antibodies - Enterotoxin B: 16 monoclonal antibodies

- Ricin toxin: 25 monoclonal antibodies (5 anti-chain A; 20 anti-Chain B) - Epsilon and proto-Epsilon toxins: 5 monoclonal antibodies

- Microcystin: 48 monoclonal antibodies Monoclonal antibodies production:

Monoclonal antibodies against 10 toxins

CBRN program

(17)

Monoclonal antibodies production:

Monoclonal antibodies against 6 pathogens

-Salmonella: 73 monoclonal antibodies -Legionella: 22 monoclonal antibodies -Shigella: 12 monoclonal antibodies

-Burkholderia pseudo-mallei: 28 monoclonal antibodies -Yersinia pestis: 26 monoclonal antibodies

-Bacillus anthracis: 64 monoclonal antibodies

CBRN program

(18)

18

Classical immunoassays

0 5000 10000 15000 20000

0.00 0.25 0.50 0.75 1.00 1.25 1.50

pg/ml Absorbance (414 nm)

Toxins

- Botulinum neurotoxin A: 40 pg/ml - Botulinum neurotoxin B: 70 pg/ml - Botulinum neurotoxin E: 100 pg/ml - Botulinum neurotoxin F: 40 pg/ml -Enterotoxin B: 25 pg/ml

-Ricin toxin: 30 pg/ml -Microcystin: 25 pg/ml -Epsilon toxin: 10 pg/ml

-proto-Epsilon toxin: 10 pg/ml Pathogens -Salmonella: 2 105

-Bacillus anthracis: 104 sp/ml -Yersinia pestis: 3 104 cfu/ml -Legionella: 104

CBRN program

(19)

19

Toxins

- Botulinum neurotoxin A: 2,5 ng/ml - Botulinum neurotoxin B: 2,5 ng/ml - Botulinum neurotoxin E: 5 ng/ml - Enterotoxin B: 1 ng/ml

- Ricin toxin: 1 ng/ml - Microcystin: 2 ng/ml - Epsilon toxin: 100pg/ml

- proto-Epsilon toxin: 100pg/ml Pathogens

-Salmonella: 5 103

-Bacillus anthracis: 5 105 sp/ml -Yersinia pestis: 106cfu/ml -Legionella: 105

Lateral flow immunoassays

CBRN program

+ -

(20)

20 SPI/LERI Référence… 07/21/2011

Creation of a new platform:

(21)

ProdIg platform

21

-Robot for monoclonal production

(22)

22

ProdIg platform

-BSL3 facilities

Pathogens culture and characterization

Pathogen components and toxins purification Immunoassays validation

Monoclonal antibodies production against alive pathogens and neutralizing activity evaluation

(23)

Thank you for your attention

23

Referenzen

ÄHNLICHE DOKUMENTE

There was no association between onset of therapy with the effect size, Wilcoxon matched-pairs signed rank test, p = 0.2406; (D) Association of weighted effect size scores with

Correlation of the pregnancy-associated plasma protein A (PAPP-A) concentration values in normal first trimester pregnancy serum obtained in a comparison between the double-

This article summarizes clinical trials on immunotherapy of pancreatic cancer using the murine monoclonal antibodies (MAbs) 17-1A and BW 494. In addition, the use of MAb

Based on these considerations, the aim of the present study was defined as an evaluation of different types of filling systems (piston pump, radial peristaltic pump and linear

As a consequence of chiral symmetry, the leading order interaction between an narrow excited heavy meson and the kaon should be the same as that for the ground state charmed mesons

cruzi epimastigote specific monoclonal antibody, 2A2, which reacts with both culture and insect derived epimastigotes provides a more reliable basis for differential diagnosis of

Summary The metacyclic trypanosomes of a Trypanosoma brucei brucei clone ILTat 2.1 were analysed with regard to their variable antigen VAT composition using monoclonal antibodies..

ü We have cloned human full-length tyrosinase cDNA and its truncated form into eukaryotic expression vector for gene expression and further immunization studies against